Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: J Stroke Cerebrovasc Dis. 2021 Jan 12;30(3):105595. doi: 10.1016/j.jstrokecerebrovasdis.2020.105595

Figure 3. Plasma MMP-9 is related to HT and reduced by glibenclamide in cohort 1.

Figure 3.

(A) Plasma total MMP-9 was lowered by continuous glibenclamide administration (* p<0.05). (B) Plasma MMP-9 was elevated in tMCAO animals that had HT compared to those that did not (** p<0.01), and (C) there was a stepwise relationship with the severity of HT categories (* p<0.05).